Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)

Therapeutics

Life Sciences

Health Care

Biotechnology

SYLENTIS

SYLENTIS' headquarters in Tres Cantos, Spain

Description

People (1)

Jobs (0)

Other offices